Cost and cost-effectiveness of childhood vaccination against rotavirus in France
Summary Objectives To assess the effectiveness and cost-effectiveness of routine childhood vaccination by new vaccines against rotavirus in France. Methods We constructed a Markov decision tree to compare two alternatives: “no vaccination” and “vaccination”. A hypothetical birth cohort of 750,000 ch...
Gespeichert in:
| Veröffentlicht in: | Vaccine 2008-01, Vol.26 (5), p.706-715 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 715 |
|---|---|
| container_issue | 5 |
| container_start_page | 706 |
| container_title | Vaccine |
| container_volume | 26 |
| creator | Melliez, H Levybruhl, D Boelle, P.Y Dervaux, B Baron, S Yazdanpanah, Y |
| description | Summary Objectives To assess the effectiveness and cost-effectiveness of routine childhood vaccination by new vaccines against rotavirus in France. Methods We constructed a Markov decision tree to compare two alternatives: “no vaccination” and “vaccination”. A hypothetical birth cohort of 750,000 children was followed until 3 years of age. First, the disease burden without vaccine was estimated using data from French databases and medical literature. Incidence rates in unvaccinated children were modelled as a function of age and seasons. Next, using data from the medical literature, the vaccine's protective effect on rotavirus diarrhoea was considered. Results A routine universal rotavirus immunization programme was estimated capable of annually avoiding 89,000 cases of diarrhoea, 10,500 hospitalizations, and 8 deaths. At a vaccination cost of €150/course, assuming 75% vaccine coverage, the programme would cost €95 million and involve a net loss of €68 million to the health care system. The vaccination programme would cost €298,000/year of life saved, and €138,000/QALY saved. Key variables affecting the results were disease incidence, mortality rates and vaccine price. Conclusion In France, childhood rotavirus vaccination with new antirotavirus vaccines would reduce the morbidity burden of rotavirus infection, but would not be cost-effective unless the price of vaccine decreased considerably. |
| doi_str_mv | 10.1016/j.vaccine.2007.11.064 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_hal_p</sourceid><recordid>TN_cdi_hal_primary_oai_HAL_hal_00283456v1</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0264410X07013436</els_id><sourcerecordid>20986868</sourcerecordid><originalsourceid>FETCH-LOGICAL-c541t-1171e31f686ac0d3898c1c7f08e8b52b975d8f9568289815573dd1b40a0e22753</originalsourceid><addsrcrecordid>eNqFkl2L1DAUhoMo7rj6E5SCKHjRek7afPRGWQbXFQYUVPAuZNLUydhp1qQt7L83pcWBvdmrhOQ5J2_yhJCXCAUC8vfHYtLGuN4WFEAUiAXw6hHZoBRlThnKx2QDlFd5hfDrgjyL8QgArMT6KblAiZxTBhvybevjkOm-yUya5LZtrRncZHsbY-bbzBxc1xy8b7LlOD0432f6t3Z9qgt-0JMLY8xcn10H3Rv7nDxpdRfti3W8JD-vP_3Y3uS7r5-_bK92uWEVDjmiQFtiyyXXBppS1tKgES1IK_eM7mvBGtnWjEuatpAxUTYN7ivQYCkVrLwk75a-B92p2-BOOtwpr526udqpeQ2AyrJifMLEvl3Y2-D_jjYO6uSisV2ne-vHqARQrFKEB0EKtUyJZQJf3wOPfgx9urBKWaWoBRciUWyhTPAxBtv-D4qgZovqqFaLaraoEFWymOperd3H_ck256pVWwLerICORnft_PIunrm6lqyiPHEfF84mE5OzQUXjbLLUuJA8q8a7B6N8uNfBdK536dA_9s7G861VpArU9_nLzT8OBGBZlbz8By5iz3k</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1558797677</pqid></control><display><type>article</type><title>Cost and cost-effectiveness of childhood vaccination against rotavirus in France</title><source>MEDLINE</source><source>ScienceDirect Journals (5 years ago - present)</source><source>ProQuest Central UK/Ireland</source><creator>Melliez, H ; Levybruhl, D ; Boelle, P.Y ; Dervaux, B ; Baron, S ; Yazdanpanah, Y</creator><creatorcontrib>Melliez, H ; Levybruhl, D ; Boelle, P.Y ; Dervaux, B ; Baron, S ; Yazdanpanah, Y</creatorcontrib><description>Summary Objectives To assess the effectiveness and cost-effectiveness of routine childhood vaccination by new vaccines against rotavirus in France. Methods We constructed a Markov decision tree to compare two alternatives: “no vaccination” and “vaccination”. A hypothetical birth cohort of 750,000 children was followed until 3 years of age. First, the disease burden without vaccine was estimated using data from French databases and medical literature. Incidence rates in unvaccinated children were modelled as a function of age and seasons. Next, using data from the medical literature, the vaccine's protective effect on rotavirus diarrhoea was considered. Results A routine universal rotavirus immunization programme was estimated capable of annually avoiding 89,000 cases of diarrhoea, 10,500 hospitalizations, and 8 deaths. At a vaccination cost of €150/course, assuming 75% vaccine coverage, the programme would cost €95 million and involve a net loss of €68 million to the health care system. The vaccination programme would cost €298,000/year of life saved, and €138,000/QALY saved. Key variables affecting the results were disease incidence, mortality rates and vaccine price. Conclusion In France, childhood rotavirus vaccination with new antirotavirus vaccines would reduce the morbidity burden of rotavirus infection, but would not be cost-effective unless the price of vaccine decreased considerably.</description><identifier>ISSN: 0264-410X</identifier><identifier>EISSN: 1873-2518</identifier><identifier>EISSN: 0264-410X</identifier><identifier>DOI: 10.1016/j.vaccine.2007.11.064</identifier><identifier>PMID: 18166250</identifier><identifier>CODEN: VACCDE</identifier><language>eng</language><publisher>Oxford: Elsevier Ltd</publisher><subject>Allergy and Immunology ; Biological and medical sciences ; Child ; Child, Preschool ; Children & youth ; Commerce ; Cost-Benefit Analysis ; Cost-effectiveness ; Diarrhea ; Discount rates ; Economics and Finance ; France - epidemiology ; Fundamental and applied biological sciences. Psychology ; Health Care Costs ; Hospitalization ; Humanities and Social Sciences ; Humans ; Immunization ; Immunization Programs - economics ; Infant ; Markov Chains ; Microbiology ; Miscellaneous ; Models, Theoretical ; Morbidity ; Mortality ; Rotavirus ; Rotavirus Infections - economics ; Rotavirus Infections - immunology ; Rotavirus Infections - prevention & control ; Rotavirus Vaccines - economics ; Vaccination ; Vaccines ; Virology</subject><ispartof>Vaccine, 2008-01, Vol.26 (5), p.706-715</ispartof><rights>Elsevier Ltd</rights><rights>2007 Elsevier Ltd</rights><rights>2008 INIST-CNRS</rights><rights>Copyright Elsevier Limited Jan 30, 2008</rights><rights>Distributed under a Creative Commons Attribution 4.0 International License</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c541t-1171e31f686ac0d3898c1c7f08e8b52b975d8f9568289815573dd1b40a0e22753</citedby><cites>FETCH-LOGICAL-c541t-1171e31f686ac0d3898c1c7f08e8b52b975d8f9568289815573dd1b40a0e22753</cites><orcidid>0000-0002-5367-8232</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.proquest.com/docview/1558797677?pq-origsite=primo$$EHTML$$P50$$Gproquest$$H</linktohtml><link.rule.ids>230,314,780,784,885,3548,27923,27924,45994,64384,64386,64388,72240</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=19985426$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/18166250$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttps://hal.science/hal-00283456$$DView record in HAL$$Hfree_for_read</backlink></links><search><creatorcontrib>Melliez, H</creatorcontrib><creatorcontrib>Levybruhl, D</creatorcontrib><creatorcontrib>Boelle, P.Y</creatorcontrib><creatorcontrib>Dervaux, B</creatorcontrib><creatorcontrib>Baron, S</creatorcontrib><creatorcontrib>Yazdanpanah, Y</creatorcontrib><title>Cost and cost-effectiveness of childhood vaccination against rotavirus in France</title><title>Vaccine</title><addtitle>Vaccine</addtitle><description>Summary Objectives To assess the effectiveness and cost-effectiveness of routine childhood vaccination by new vaccines against rotavirus in France. Methods We constructed a Markov decision tree to compare two alternatives: “no vaccination” and “vaccination”. A hypothetical birth cohort of 750,000 children was followed until 3 years of age. First, the disease burden without vaccine was estimated using data from French databases and medical literature. Incidence rates in unvaccinated children were modelled as a function of age and seasons. Next, using data from the medical literature, the vaccine's protective effect on rotavirus diarrhoea was considered. Results A routine universal rotavirus immunization programme was estimated capable of annually avoiding 89,000 cases of diarrhoea, 10,500 hospitalizations, and 8 deaths. At a vaccination cost of €150/course, assuming 75% vaccine coverage, the programme would cost €95 million and involve a net loss of €68 million to the health care system. The vaccination programme would cost €298,000/year of life saved, and €138,000/QALY saved. Key variables affecting the results were disease incidence, mortality rates and vaccine price. Conclusion In France, childhood rotavirus vaccination with new antirotavirus vaccines would reduce the morbidity burden of rotavirus infection, but would not be cost-effective unless the price of vaccine decreased considerably.</description><subject>Allergy and Immunology</subject><subject>Biological and medical sciences</subject><subject>Child</subject><subject>Child, Preschool</subject><subject>Children & youth</subject><subject>Commerce</subject><subject>Cost-Benefit Analysis</subject><subject>Cost-effectiveness</subject><subject>Diarrhea</subject><subject>Discount rates</subject><subject>Economics and Finance</subject><subject>France - epidemiology</subject><subject>Fundamental and applied biological sciences. Psychology</subject><subject>Health Care Costs</subject><subject>Hospitalization</subject><subject>Humanities and Social Sciences</subject><subject>Humans</subject><subject>Immunization</subject><subject>Immunization Programs - economics</subject><subject>Infant</subject><subject>Markov Chains</subject><subject>Microbiology</subject><subject>Miscellaneous</subject><subject>Models, Theoretical</subject><subject>Morbidity</subject><subject>Mortality</subject><subject>Rotavirus</subject><subject>Rotavirus Infections - economics</subject><subject>Rotavirus Infections - immunology</subject><subject>Rotavirus Infections - prevention & control</subject><subject>Rotavirus Vaccines - economics</subject><subject>Vaccination</subject><subject>Vaccines</subject><subject>Virology</subject><issn>0264-410X</issn><issn>1873-2518</issn><issn>0264-410X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2008</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>8G5</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNqFkl2L1DAUhoMo7rj6E5SCKHjRek7afPRGWQbXFQYUVPAuZNLUydhp1qQt7L83pcWBvdmrhOQ5J2_yhJCXCAUC8vfHYtLGuN4WFEAUiAXw6hHZoBRlThnKx2QDlFd5hfDrgjyL8QgArMT6KblAiZxTBhvybevjkOm-yUya5LZtrRncZHsbY-bbzBxc1xy8b7LlOD0432f6t3Z9qgt-0JMLY8xcn10H3Rv7nDxpdRfti3W8JD-vP_3Y3uS7r5-_bK92uWEVDjmiQFtiyyXXBppS1tKgES1IK_eM7mvBGtnWjEuatpAxUTYN7ivQYCkVrLwk75a-B92p2-BOOtwpr526udqpeQ2AyrJifMLEvl3Y2-D_jjYO6uSisV2ne-vHqARQrFKEB0EKtUyJZQJf3wOPfgx9urBKWaWoBRciUWyhTPAxBtv-D4qgZovqqFaLaraoEFWymOperd3H_ck256pVWwLerICORnft_PIunrm6lqyiPHEfF84mE5OzQUXjbLLUuJA8q8a7B6N8uNfBdK536dA_9s7G861VpArU9_nLzT8OBGBZlbz8By5iz3k</recordid><startdate>20080130</startdate><enddate>20080130</enddate><creator>Melliez, H</creator><creator>Levybruhl, D</creator><creator>Boelle, P.Y</creator><creator>Dervaux, B</creator><creator>Baron, S</creator><creator>Yazdanpanah, Y</creator><general>Elsevier Ltd</general><general>Elsevier</general><general>Elsevier Limited</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QL</scope><scope>7RV</scope><scope>7T2</scope><scope>7T5</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88C</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AEUYN</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9-</scope><scope>K9.</scope><scope>KB0</scope><scope>LK8</scope><scope>M0R</scope><scope>M0S</scope><scope>M0T</scope><scope>M1P</scope><scope>M2O</scope><scope>M7N</scope><scope>M7P</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope><scope>1XC</scope><scope>BXJBU</scope><orcidid>https://orcid.org/0000-0002-5367-8232</orcidid></search><sort><creationdate>20080130</creationdate><title>Cost and cost-effectiveness of childhood vaccination against rotavirus in France</title><author>Melliez, H ; Levybruhl, D ; Boelle, P.Y ; Dervaux, B ; Baron, S ; Yazdanpanah, Y</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c541t-1171e31f686ac0d3898c1c7f08e8b52b975d8f9568289815573dd1b40a0e22753</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2008</creationdate><topic>Allergy and Immunology</topic><topic>Biological and medical sciences</topic><topic>Child</topic><topic>Child, Preschool</topic><topic>Children & youth</topic><topic>Commerce</topic><topic>Cost-Benefit Analysis</topic><topic>Cost-effectiveness</topic><topic>Diarrhea</topic><topic>Discount rates</topic><topic>Economics and Finance</topic><topic>France - epidemiology</topic><topic>Fundamental and applied biological sciences. Psychology</topic><topic>Health Care Costs</topic><topic>Hospitalization</topic><topic>Humanities and Social Sciences</topic><topic>Humans</topic><topic>Immunization</topic><topic>Immunization Programs - economics</topic><topic>Infant</topic><topic>Markov Chains</topic><topic>Microbiology</topic><topic>Miscellaneous</topic><topic>Models, Theoretical</topic><topic>Morbidity</topic><topic>Mortality</topic><topic>Rotavirus</topic><topic>Rotavirus Infections - economics</topic><topic>Rotavirus Infections - immunology</topic><topic>Rotavirus Infections - prevention & control</topic><topic>Rotavirus Vaccines - economics</topic><topic>Vaccination</topic><topic>Vaccines</topic><topic>Virology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Melliez, H</creatorcontrib><creatorcontrib>Levybruhl, D</creatorcontrib><creatorcontrib>Boelle, P.Y</creatorcontrib><creatorcontrib>Dervaux, B</creatorcontrib><creatorcontrib>Baron, S</creatorcontrib><creatorcontrib>Yazdanpanah, Y</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Nursing & Allied Health Database</collection><collection>Health and Safety Science Abstracts (Full archive)</collection><collection>Immunology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Healthcare Administration Database (Alumni)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest One Sustainability</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>ProQuest Biological Science Collection</collection><collection>Consumer Health Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Healthcare Administration Database</collection><collection>Medical Database</collection><collection>Research Library</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>Hyper Article en Ligne (HAL)</collection><collection>HAL-SHS: Archive ouverte en Sciences de l'Homme et de la Société</collection><jtitle>Vaccine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Melliez, H</au><au>Levybruhl, D</au><au>Boelle, P.Y</au><au>Dervaux, B</au><au>Baron, S</au><au>Yazdanpanah, Y</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Cost and cost-effectiveness of childhood vaccination against rotavirus in France</atitle><jtitle>Vaccine</jtitle><addtitle>Vaccine</addtitle><date>2008-01-30</date><risdate>2008</risdate><volume>26</volume><issue>5</issue><spage>706</spage><epage>715</epage><pages>706-715</pages><issn>0264-410X</issn><eissn>1873-2518</eissn><eissn>0264-410X</eissn><coden>VACCDE</coden><abstract>Summary Objectives To assess the effectiveness and cost-effectiveness of routine childhood vaccination by new vaccines against rotavirus in France. Methods We constructed a Markov decision tree to compare two alternatives: “no vaccination” and “vaccination”. A hypothetical birth cohort of 750,000 children was followed until 3 years of age. First, the disease burden without vaccine was estimated using data from French databases and medical literature. Incidence rates in unvaccinated children were modelled as a function of age and seasons. Next, using data from the medical literature, the vaccine's protective effect on rotavirus diarrhoea was considered. Results A routine universal rotavirus immunization programme was estimated capable of annually avoiding 89,000 cases of diarrhoea, 10,500 hospitalizations, and 8 deaths. At a vaccination cost of €150/course, assuming 75% vaccine coverage, the programme would cost €95 million and involve a net loss of €68 million to the health care system. The vaccination programme would cost €298,000/year of life saved, and €138,000/QALY saved. Key variables affecting the results were disease incidence, mortality rates and vaccine price. Conclusion In France, childhood rotavirus vaccination with new antirotavirus vaccines would reduce the morbidity burden of rotavirus infection, but would not be cost-effective unless the price of vaccine decreased considerably.</abstract><cop>Oxford</cop><pub>Elsevier Ltd</pub><pmid>18166250</pmid><doi>10.1016/j.vaccine.2007.11.064</doi><tpages>10</tpages><orcidid>https://orcid.org/0000-0002-5367-8232</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0264-410X |
| ispartof | Vaccine, 2008-01, Vol.26 (5), p.706-715 |
| issn | 0264-410X 1873-2518 0264-410X |
| language | eng |
| recordid | cdi_hal_primary_oai_HAL_hal_00283456v1 |
| source | MEDLINE; ScienceDirect Journals (5 years ago - present); ProQuest Central UK/Ireland |
| subjects | Allergy and Immunology Biological and medical sciences Child Child, Preschool Children & youth Commerce Cost-Benefit Analysis Cost-effectiveness Diarrhea Discount rates Economics and Finance France - epidemiology Fundamental and applied biological sciences. Psychology Health Care Costs Hospitalization Humanities and Social Sciences Humans Immunization Immunization Programs - economics Infant Markov Chains Microbiology Miscellaneous Models, Theoretical Morbidity Mortality Rotavirus Rotavirus Infections - economics Rotavirus Infections - immunology Rotavirus Infections - prevention & control Rotavirus Vaccines - economics Vaccination Vaccines Virology |
| title | Cost and cost-effectiveness of childhood vaccination against rotavirus in France |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-11T10%3A56%3A46IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_hal_p&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Cost%20and%20cost-effectiveness%20of%20childhood%20vaccination%20against%20rotavirus%20in%20France&rft.jtitle=Vaccine&rft.au=Melliez,%20H&rft.date=2008-01-30&rft.volume=26&rft.issue=5&rft.spage=706&rft.epage=715&rft.pages=706-715&rft.issn=0264-410X&rft.eissn=1873-2518&rft.coden=VACCDE&rft_id=info:doi/10.1016/j.vaccine.2007.11.064&rft_dat=%3Cproquest_hal_p%3E20986868%3C/proquest_hal_p%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1558797677&rft_id=info:pmid/18166250&rft_els_id=S0264410X07013436&rfr_iscdi=true |